Source:http://linkedlifedata.com/resource/pubmed/id/17470361
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2007-5-15
|
pubmed:abstractText |
Cisplatin (CDDP) and its analogues are widely used for the treatment of a variety of human solid tumors. However, the molecular mechanism of its action remains to be understood. Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis and is upregulated in many human cancers. In this study we demonstrated that CDDP-inhibited VEGF expression in human ovarian cancer cells. We found that CDDP inhibited the VEGF reporter activity in a dose-dependent manner, indicating that CDDP-inhibited transcriptional activation of VEGF. We also found that: (1) luciferase activity mediated by the VEGF reporter containing a mutation of the HIF-1 binding site was much lower than that of the reporter containing a wild-type HIF-1 binding site in ovarian cancer cells, thus confirming that HIF-1 is a major transcriptional regulator of VEGF expression; and that (2) CDDP greatly inhibited VEGF reporter activity containing the wild-type but not the mutant HIF-1 binding site. This result indicates that CDDP-inhibited VEGF transcriptional activation specifically by decreasing HIF-1 activity. Co-transfection of a dominant negative construct of HIF-1 inhibited VEGF reporter activity in ovarian cancer cells. CDDP-inhibited VEGF transcriptional activation specifically through the expression of HIF-1alpha, but not HIF-1beta. We demonstrated that VEGF receptor KDR was expressed in ovarian cancer cells, and that CDDP-inhibited VEGF expression was linked with cellular apoptosis, which was rescued by VEGF treatment. These results suggest a novel mechanism of CDDP's anti-tumor activity in ovarian cancer cells via HIF-1 expression and VEGF transcriptional activation.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ARNT protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aryl Hydrocarbon Receptor Nuclear...,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/HIF1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Hypoxia-Inducible Factor 1, alpha...,
http://linkedlifedata.com/resource/pubmed/chemical/Luciferases,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor...
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0006-291X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
22
|
pubmed:volume |
358
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
92-8
|
pubmed:dateRevised |
2009-11-19
|
pubmed:meshHeading |
pubmed-meshheading:17470361-Antineoplastic Agents,
pubmed-meshheading:17470361-Apoptosis,
pubmed-meshheading:17470361-Aryl Hydrocarbon Receptor Nuclear Translocator,
pubmed-meshheading:17470361-Cell Line, Tumor,
pubmed-meshheading:17470361-Cisplatin,
pubmed-meshheading:17470361-Female,
pubmed-meshheading:17470361-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:17470361-Humans,
pubmed-meshheading:17470361-Hypoxia-Inducible Factor 1, alpha Subunit,
pubmed-meshheading:17470361-Luciferases,
pubmed-meshheading:17470361-Mutation,
pubmed-meshheading:17470361-Ovarian Neoplasms,
pubmed-meshheading:17470361-Vascular Endothelial Growth Factor Receptor-2
|
pubmed:year |
2007
|
pubmed:articleTitle |
Mechanism of vascular endothelial growth factor expression mediated by cisplatin in human ovarian cancer cells.
|
pubmed:affiliation |
Laboratory of Reproductive Medicine, Cancer Center, Nanjing Medical University, Nanjing 210029, Jiangsu, China.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|